Importantly, by applying a publicly available GM-CSF signature89 (Supplementary Data 9) to NrasG12D/PtenKO bulk tumor and CD45+ RNA-seq datasets (Supplementary Data 9), we confirmed the significant enrichment of GM-CSF downstream pathways in this HCC model (Fig. 5e). This evidence concerns the gene PTPRC and hepatocellular carcinoma.